
Please try another search
Investing.com -- Novartis (SIX:NOVN) stock rose 2.2% on Monday after the pharmaceutical giant announced positive top-line results from two Phase III clinical trials evaluating ianalumab in adults...
Investing.com -- Morgan Stanley (NYSE:MS) on Friday issued contrasting ratings changes for two of Switzerland’s pharmaceutical giants, upgrading Novartis AG (SIX:NOVN) while cutting Roche...
Investing.com -- Novartis (SIX:NOVN) on Thursday posted a 24% rise in second-quarter net income to $4 billion, as sales of key therapies including Kisqali and Entresto drove performance in the...
Investing.com - Shares of European drugmakers slipped on Wednesday after U.S. President Donald Trump said that tariffs of up to 200% on pharmaceutical imports could be coming "very soon." In...
Investing.com -- Novartis (SIX:NOVN) received approval in Switzerland for Coartem Baby, the first drug specifically designed to treat malaria in babies and young children. The pharmaceutical...
Investing.com -- Novartis (SIX:NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage trial for patients with an earlier form of advanced prostate cancer. The...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review